Physician profile
Kira M Campos
NPI 1942501580
$2,681.25
in general payments reported to CMS, 2019-2025
20 companies · $705 in 2025
The $705 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.72 · 2022: $424 · 2023: $818 · 2024: $683 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.80 | 2023-2025 | Tagrisso |
| Incyte Corporation | $242.97 | 2022-2024 | Pemazyre |
| Lilly USA, LLC | $170.35 | 2023-2024 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $167.42 | 2021-2025 | Libtayo |
| Genzyme Corporation | $149.56 | 2022 | |
| Genentech USA, INC. | $138.78 | 2023 | Polivy, Lunsumio |
| Beone Medicines USA, INC. | $133.68 | 2025 | Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $126.74 | 2023 | |
| Beigene USA, INC. | $125.24 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $124.97 | 2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $124.52 | 2023 | Reblozyl |
| Sobi, INC | $124.18 | 2025 | |
| Pharmacosmos Therapeutics INC. | $121.19 | 2024 | Monoferric |
| Karyopharm Therapeutics INC. | $121.18 | 2022-2023 | Xpovio |
| Deciphera Pharmaceuticals INC. | $119.30 | 2024 | Qinlock |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Abbvie INC. | $62.37 | 2022-2023 | |
| Glaxosmithkline, LLC. | $22.82 | 2021 | |
| Ucb, INC. | $22.67 | 2022 | |
| Seagen INC. | $21.51 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kira Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.